Published in PLoS One on April 23, 2008
Effect of Interleukin-2 on HIV Treatment Interruption | NCT00015704
Novel clinical trial designs for the development of new antiretroviral agents. AIDS (2012) 2.01
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis (2011) 1.91
Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol (2009) 1.63
The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol (2009) 1.55
Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr (2009) 1.16
Immune activation and collateral damage in AIDS pathogenesis. Front Immunol (2013) 1.08
Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol (2012) 0.94
HIV treatment for prevention. J Int AIDS Soc (2011) 0.93
Spiritual and mind-body beliefs as barriers and motivators to HIV-treatment decision-making and medication adherence? A qualitative study. AIDS Patient Care STDS (2009) 0.90
Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 0.89
The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. AIDS (2010) 0.89
Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. World J Virol (2013) 0.88
Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. AIDS (2009) 0.86
HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol (2012) 0.84
A prospective cohort study of periodontal disease measures and cardiovascular disease markers in HIV-infected adults. AIDS Res Hum Retroviruses (2011) 0.83
Management of dyslipidemia in HIV-infected patients. Clin Lipidol (2011) 0.83
Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol (2016) 0.82
Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J Clin Endocrinol Metab (2012) 0.81
Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems. Cholesterol (2010) 0.81
Inflammatory Markers Associated With Subclinical Coronary Artery Disease: The Multicenter AIDS Cohort Study. J Am Heart Assoc (2016) 0.80
Switching antiretroviral therapy to minimize metabolic complications. HIV Ther (2010) 0.80
Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children. Antivir Ther (2013) 0.79
Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults. J Virol (2014) 0.76
Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients. PLoS One (2017) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Inflammation and atherosclerosis. Circulation (2002) 20.77
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Chronic infections and coronary heart disease: is there a link? Lancet (1997) 7.18
Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med (2005) 6.49
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med (1991) 6.13
Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med (2003) 5.88
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis (2000) 4.88
Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 4.01
Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol (2006) 3.48
Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis (2002) 2.46
Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation (1997) 2.22
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis (2004) 1.37
Production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) in patients with AIDS. Enhanced level of TNF-alpha is related to a higher cytotoxic activity. Clin Exp Immunol (1989) 1.35
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr (2006) 1.06
Structured intermittent treatment for HIV disease: Necessary concession or premature compromise? Proc Natl Acad Sci U S A (2002) 0.99
Does HIV cause cardiovascular disease? PLoS Med (2006) 0.92
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med (2009) 4.54
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21
Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol (2004) 3.28
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis (2011) 2.60
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr (2004) 2.55
Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis (2011) 2.54
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS (2010) 2.33
Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS (2003) 2.20
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis (2011) 2.12
Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis (2007) 2.05
Nontuberculous pyogenic spinal infection in adults: a 12-year experience from a tertiary referral center. Spine (Phila Pa 1976) (2006) 2.00
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr (2007) 1.98
Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis (2005) 1.95
Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood (2002) 1.94
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS (2010) 1.83
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One (2011) 1.82
Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol (2004) 1.75
Switching effective antiretroviral therapy: a review. Clin Infect Dis (2002) 1.66
Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS (2004) 1.65
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis (2004) 1.57
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis (2006) 1.57
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis (2005) 1.56
Drug resistance in non-subtype B HIV-1. J Clin Virol (2004) 1.56
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis (2011) 1.53
The incidence and correlates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries. Sex Transm Dis (2011) 1.50
Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J Immunol (2004) 1.50
CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol (2003) 1.48
Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS One (2010) 1.46
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. AIDS (2007) 1.45
The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest (2004) 1.45
Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis (2005) 1.43
Factors in the delayed HIV presentation of immigrants in Northern California: implications for voluntary counseling and testing programs. J Immigr Minor Health (2007) 1.41
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis (2011) 1.40
Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods (2009) 1.38
Determination of ephedra alkaloids by liquid chromatography/tandem mass spectrometry. J AOAC Int (2003) 1.38
Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr (2012) 1.38
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med (2002) 1.36
HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses (2005) 1.31
Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses (2007) 1.31
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One (2010) 1.30
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis (2004) 1.30
Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health (2011) 1.30
CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol (2002) 1.24
Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS (2013) 1.23
Reducing plasma HIV RNA improves muscle amino acid metabolism. Am J Physiol Endocrinol Metab (2004) 1.22
Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev (2003) 1.20
Primary drug resistance in South Africa: data from 10 years of surveys. AIDS Res Hum Retroviruses (2012) 1.20
Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS (2011) 1.19
Quality of life, psychosocial health, and antiretroviral therapy among HIV-positive women in Zimbabwe. AIDS Care (2009) 1.16
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses (2008) 1.15
Whole-body proteolysis rate is elevated in HIV-associated insulin resistance. Diabetes (2006) 1.14
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr (2005) 1.13
HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr (2012) 1.12
HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses (2007) 1.11
HIV disclosure patterns, predictors, and psychosocial correlates among HIV positive women in Zimbabwe. AIDS Care (2011) 1.11
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis (2004) 1.10
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother (2006) 1.08
Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. Clin Infect Dis (2012) 1.07
Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing. Clin Infect Dis (2013) 1.06
A North American multilaboratory study of CD4 counts using flow cytometric panLeukogating (PLG): a NIAID-DAIDS Immunology Quality Assessment Program Study. Cytometry B Clin Cytom (2008) 1.06
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr (2006) 1.06
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis (2013) 1.06
TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods (2009) 1.06
Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther (2009) 1.06
Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. AIDS (2003) 1.04
Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res Hum Retroviruses (2005) 1.03
Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? Clin Infect Dis (2008) 1.03
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol (2014) 1.03
Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS (2004) 1.03
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis (2002) 1.03
Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic. AIDS (2006) 1.02
Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis (2004) 1.02
Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism (2005) 1.00
Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. Am J Physiol Endocrinol Metab (2003) 1.00
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses (2004) 1.00
Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe. AIDS (2009) 1.00
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis (2013) 0.99
HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res Hum Retroviruses (2007) 0.99
A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr (2004) 0.99
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses (2002) 0.98
Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl (2011) 0.98
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr (2013) 0.96
Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. J AIDS Clin Res (2011) 0.96
Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr (2002) 0.96
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis (2012) 0.96